The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. BERLIN — For years, scientists have held out hope that tests that look ...

Bladder cancer does not always announce itself with dramatic pain or a sudden health crisis. In many people, the earliest bladder cancer symptoms look ordinary, brief, or easy to dismiss. A little ...

Researchers at the University of Birmingham believe that a simple urine test could help to guide clinicians in the treatment of bladder cancer patients. Being able to reliably identify those patients ...

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

Cellens, a Boston, MA-based cancer diagnostics startup, has raised a $6.5 million seed round. The company is developing a mechanobiology and AI-driven platform, BioFeel, for non-invasive cancer ...

Scientists in Newcastle, where the test was developed, hailed it as a "revolution" A pioneering test is improving early diagnosis for people with hereditary cancer caused by a genetic condition. Just ...

Results of two phase 3 studies — IMvigor011 and DYNAMIC-III — presented at the European Society for Medical Oncology (ESMO) Annual Meeting 2025 suggest that circulating tumor DNA (ctDNA) could help ...

The founder said that 50% of enrolled patients in the Phase 3 bladder cancer study reached an evaluable efficacy endpoint, ...

Some claim the new multi-cancer detection tests will “revolutionize” cancer screening. Others fear the “worried well” will succumb to slick marketing and subpar tests and overwhelm both primary care ...